Big Data is becoming increasingly relevant for the healthcare industry, and although it raises new challenges for data protection and data analytics, the potential for diagnostics is huge.
Launched in 2011, Sophia Genetics is a Swiss-based analytics company that is using AI to accelerate diagnostics in oncology, hereditary cancer, metabolic disorders, pediatrics and cardiology via DNA sequencing, and could be the tiny mountainous country’s next big win in the tech industry. Sophia Genetics is betting on powerful AI algorithms and a global community of hospitals to move diagnostics forward.
The process (which takes two days rather than the existing technology’s timeframe of several months) begins with the extraction of the patient’s DNA via a blood draw or biopsy.
The hospital then prepares samples and processes them using a DNA sequencer. That data is then entered into the Sophia DDM platform, which uses its AI to dig around and identify the mutations in the patient’s genome. “The more hospitals use the analytical platform, the more genomic profiles it analyzes, and the smarter the AI gets,” explains Camblong.
Since Sophia DDM is a software-as-a-service platform, aren’t paying annual licensing fees for technology they use infrequently. They simply create a login and pay a fee whenever they use it to enter a new sample. Fees range between $50-200 a test.
There are about 215 hospitals from 35 countries, including France, Italy, Brazil and South Africa, that are using the platform today.